Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -30,775 | -34,714 | -41,904 | -37,992 | -18,433 |
| Depreciation Amortization | 65 | 112 | 268 | 240 | 225 |
| Accounts receivable | N/A | N/A | N/A | N/A | -113 |
| Accounts payable and accrued liabilities | 639 | 806 | -1,185 | 246 | 14 |
| Other Working Capital | 971 | -2,044 | 2,099 | -102 | 470 |
| Other Operating Activity | 2,451 | 2,594 | 7,973 | 13,261 | 5,642 |
| Operating Cash Flow | $-26,649 | $-33,246 | $-32,749 | $-24,347 | $-12,195 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | 148 | -221 | -187 | -363 |
| Investing Cash Flow | $0 | $148 | $-221 | $-187 | $-363 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,996 | 26,989 | 19,744 | 44,310 | 23,456 |
| Financing Cash Flow | $4,996 | $26,989 | $19,744 | $44,310 | $23,456 |
| Beginning Cash Position | 33,729 | 39,838 | 53,064 | 33,288 | 22,390 |
| End Cash Position | 12,076 | 33,729 | 39,838 | 53,064 | 33,288 |
| Net Cash Flow | $-21,653 | $-6,109 | $-13,226 | $19,776 | $10,898 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,649 | -33,246 | -32,749 | -24,347 | -12,195 |
| Capital Expenditure | 0 | -4 | -221 | -187 | -364 |
| Free Cash Flow | -26,649 | -33,250 | -32,970 | -24,534 | -12,559 |